Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 993

1.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

2.

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA).

Blood. 2005 Dec 1;106(12):3755-9. Epub 2005 Aug 16.

3.

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe.

J Clin Oncol. 2005 Dec 20;23(36):9227-33. Epub 2005 Nov 7.

4.

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC.

Blood. 1998 Nov 1;92(9):3131-6.

5.

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R.

N Engl J Med. 1996 Jul 11;335(2):91-7.

6.

Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.

Galli M, Nicolucci A, Valentini M, Belfiglio M, Delaini F, Crippa C, Barbui AM, Giussani U, Rambaldi A, Barbui T.

Haematologica. 2005 Dec;90(12):1643-9.

7.
8.

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.

J Clin Oncol. 1994 Nov;12(11):2405-14.

PMID:
7964957
9.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome.

Blood. 2002 Feb 1;99(3):731-5.

10.

Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.

Bladé J, San Miguel JF, Fontanillas M, Alcalá A, Maldonado J, García-Conde J, Conde E, Conzález-Brito G, Moro MJ, Escudero ML, Trujillo J, Pascual A, Rozman C, Estapé J, Montserrat E.

J Clin Oncol. 1996 Jul;14(7):2167-73.

PMID:
8683251
11.

Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

Ballestrero A, Ferrando F, Miglino M, Clavio M, Gonella R, Garuti A, Grasso R, Ghio R, Balleari E, Gobbi M, Patrone F.

Eur J Haematol. 2002 Feb;68(2):101-6.

PMID:
12038448
12.

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.

Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K.

J Clin Oncol. 2002 Nov 15;20(22):4413-9.

PMID:
12431962
13.

Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.

Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).

Eur J Haematol. 2008 Mar;80(3):227-35. Epub 2007 Dec 18.

PMID:
18088400
14.
15.

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Rizzoli V, et al.

J Clin Oncol. 1998 Aug;16(8):2796-802.

PMID:
9704732
16.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951
17.

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.

Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, Musson H, Teodorovic I, Maes B, Carbone A, Carde P, Thomas J.

J Natl Cancer Inst. 2001 Jan 3;93(1):22-30.

19.

High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.

Gianni AM, Tarella C, Bregni M, Siena S, Lombardi F, Gandola L, Caracciolo D, Stern A, Bonadonna G, Boccadoro M, et al.

J Clin Oncol. 1994 Mar;12(3):503-9.

PMID:
8120548
20.

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

Alegre A, Díaz-Mediavilla J, San-Miguel J, Martínez R, García Laraña J, Sureda A, Lahuerta JJ, Morales D, Bladé J, Caballero D, De la Rubia J, Escudero A, Díez-Martín JL, Hernández-Navarro F, Rifón J, Odriozola J, Brunet S, De la Serna J, Besalduch J, Vidal MJ, Solano C, Leon A, Sánchez JJ, Martínez-Chamorro C, Fernández-Rañada JM.

Bone Marrow Transplant. 1998 Jan;21(2):133-40.

Items per page

Supplemental Content

Write to the Help Desk